The journey from pharmaceutical product development to Marketing Authorisation (MA) approval in the UK and EU is a highly structured regulatory process governed by scientific, technical, and legal requirements. Success depends not only on the completeness of the dossier but also on its internal consistency, regulatory alignment, and ability to withstand detailed scientific scrutiny.
Today, regulatory submissions are managed through the Electronic Common Technical Document (eCTD), the internationally recognised standard for submitting, reviewing, and maintaining medicinal product dossiers. Regulatory authorities expect applications to be complete, scientifically justified, internally consistent, and technically compliant with eCTD requirements.
Even minor gaps in Quality (CMC), clinical justification, non-clinical evidence, or administrative documentation can lead to Requests for Information (RFIs), assessment delays, or refusal risks.
Sciom provides end-to-end regulatory support that transforms this complex pathway into a controlled, predictable process from initial gap analysis through CTD dossier preparation, submission, RFI response management, and final approval support.
Understanding the Regulatory Framework for UK/EU Submissions
Applications are submitted in the Common Technical Document (CTD) format and maintained electronically through the Electronic Common Technical Document (eCTD), comprising:
- Module 1: Regional Administrative Information
- Module 2: Quality, Non-Clinical and Clinical Summaries
- Module 3: Quality (CMC)
- Module 4: Non-Clinical Documentation
- Module 5: Clinical Documentation
Given the increasing complexity of regulatory expectations, proactive assessment of dossier readiness and regulatory compliance is critical to minimizing assessment risks and accelerating approval timelines.
Regulatory Gap Analysis and Submission Readiness
A comprehensive gap analysis provides the foundation for a successful regulatory strategy. SCIOM performs detailed scientific and regulatory assessments of CTD dossiers to identify deficiencies, selection of correct reference product, evaluate compliance with current UK and EU requirements, and mitigate potential regulatory risks before submission.
Our assessments focus on:
- Completeness and integrity of CTD documentation
- Scientific consistency across modules
- Selection of correct reference product
- Compliance with current regulatory guidelines and expectations
- Adequacy of pharmaceutical development and control strategies
- Identification of potential deficiencies likely to generate Requests for Information (RFIs)
This early-stage review enables the development of targeted remediation plans and submission strategies that enhance dossier quality and regulatory readiness.
Scientific Review of CTD Modules
Module 1 – Administrative and Regulatory Compliance
Assessment of region-specific administrative documentation, including application forms, product information, manufacturing authorisations, valid GMP compliance, pharmacovigilance systems, Risk Management Plans (RMPs), and regulatory declarations.
Module 2 – Integrated Scientific Evaluation
Critical review of Quality Overall Summaries (QOS), Non-Clinical Overviews, and Clinical Overviews to ensure alignment with supporting data and the presentation of a clear and scientifically justified benefit-risk profile.
Module 3 – Quality (CMC) Assessment
Comprehensive evaluation of active substance and finished product documentation, including:
- Pharmaceutical development
- Manufacturing processes and control strategies
- Critical Quality Attributes (CQAs) and Critical Process Parameters (CPPs)
- Analytical method validation
- Specification justification
- Impurity control strategies
- Nitrosamine risk assessments
- Elemental Impurity risk assessment
- Stability studies and shelf-life justification
Particular emphasis is placed on identifying areas commonly challenged by regulatory authorities, including process validation, specification setting, impurity qualification, and lifecycle management strategies.
Modules 4 and 5 – Non-Clinical and Clinical Assessment
Scientific review of non-clinical and clinical evidence to ensure the adequacy of safety, efficacy, pharmacokinetic, and bioequivalence data, supported by appropriate statistical and scientific justification.
eCTD Publishing and Submission Management
SCIOM provides end-to-end eCTD publishing and regulatory operations support, ensuring compliance with technical validation requirements and lifecycle management standards.
Services include:
- eCTD compilation and publishing
- XML backbone and metadata verification
- Hyperlink and bookmark validation
- Lifecycle sequence management
- Submission readiness assessments
- Technical validation support
Regulatory Assessment and RFI Management
Regulatory assessment frequently involves Requests for Information (RFIs) addressing scientific, technical, or procedural aspects of the application. SCIOM supports clients through the complete response process by:
- Interpreting regulatory concerns and preparing action plans
- Developing scientifically robust justifications
- Guide on additional data generation
- Coordinating multidisciplinary subject matter experts
- Updating CTD documentation and supporting evidence
- Managing submission timelines and response strategies
Our objective is to transform regulatory questions into opportunities to strengthen the scientific position of the dossier and facilitate approval.
Post-Approval Lifecycle Management
Regulatory compliance extends beyond initial approval. SCIOM supports ongoing lifecycle management activities, including:
- Variations (Type IA, IB and II)
- Manufacturing and analytical changes
- Safety-related updates
- Product information maintenance
- Renewals and regulatory compliance activities
Through a science-driven and risk-based approach, SCIOM helps pharmaceutical companies maintain regulatory compliance while supporting efficient product lifecycle management across UK and EU markets.
Why SCIOM?
SCIOM combines scientific expertise, regulatory intelligence, CMC knowledge, and regulatory operations excellence to deliver tailored solutions throughout the product lifecycle. From early-stage gap analysis and dossier development to regulatory approval and post-authorisation maintenance, we help clients navigate complex regulatory requirements with confidence, efficiency, and scientific rigour.
Conclusion
Successful regulatory submissions require a combination of scientific rigour, regulatory expertise, technical compliance, and proactive lifecycle management.
By integrating strategic regulatory planning, CTD and eCTD expertise, scientific review, and regulatory operations support, SCIOM helps pharmaceutical companies navigate UK and EU regulatory requirements efficiently and confidently.
From gap analysis to approval and beyond, SCIOM delivers tailored regulatory solutions that support submission success, compliance, and long-term product lifecycle management.
Frequently Asked Questions (FAQs)
References
- NIH ClinRegs - United Kingdom Clinical Research Regulations (updated 2025)
- MHRA - National Assessment Procedure for Medicines (Updated April 2026)
- MHRA - Apply for a Licence to Market a Medicine in the UK
- Reform of the EU pharmaceutical legislation | European Medicines Agency (EMA)
- Electronic Common Technical Document (eCTD) submissions update - GOV.UK
- Post opinion: Regulatory and procedural guidance | European Medicines Agency (EMA)